ClinVar Miner

Submissions for variant NM_024675.4(PALB2):c.3048del (p.Phe1016fs)

dbSNP: rs515726104
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000129785 SCV000184594 pathogenic Hereditary cancer-predisposing syndrome 2019-01-08 criteria provided, single submitter clinical testing The c.3048delT pathogenic mutation, located in coding exon 10 of the PALB2 gene, results from a deletion of one nucleotide at nucleotide position 3048, causing a translational frameshift with a predicted alternate stop codon (p.F1016Lfs*17). This alteration has been reported in an African American woman diagnosed with invasive breast cancer at age 60 who also had a family history of pancreatic cancer (Zheng Y et al. Cancer 2012;118:1362-70). This variant was also reported in an African American woman with triple negative breast cancer diagnosed over the age of 45 (Churpek JE et al. Breast Cancer Res. Treat. 2015 Jan;149:31-9). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Counsyl RCV000114587 SCV000489479 pathogenic Familial cancer of breast 2016-10-11 criteria provided, single submitter clinical testing
GeneDx RCV000412897 SCV000490686 pathogenic not provided 2022-02-04 criteria provided, single submitter clinical testing Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Observed in individuals with a personal or family history consistent with pathogenic variants in this gene (Zheng 2012, Tung 2015); Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 21932393, 25186627, 25428789, 24870022, 22692731, 29625052, 26689913, 32339256, 30287823, 30128536, 29486991)
Invitae RCV000114587 SCV000633397 pathogenic Familial cancer of breast 2021-12-17 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Phe1016Leufs*17) in the PALB2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PALB2 are known to be pathogenic (PMID: 17200668, 17200671, 17200672, 24136930, 25099575). This variant is present in population databases (rs515726104, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 21932393, 25428789). ClinVar contains an entry for this variant (Variation ID: 126707). For these reasons, this variant has been classified as Pathogenic.
Color Diagnostics, LLC DBA Color Health RCV000129785 SCV000686004 pathogenic Hereditary cancer-predisposing syndrome 2020-12-02 criteria provided, single submitter clinical testing This variant deletes 1 nucleotide in exon 10 of the PALB2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with breast or ovarian cancer (PMID: 25428789, 27153395, 30287823, 30128536). This variant has been identified in 1/246228 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of PALB2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000412897 SCV001134549 pathogenic not provided 2019-03-23 criteria provided, single submitter clinical testing The variant results in a shift of the reading frame, and is therefore predicted to result in the loss of a functional protein. Found in at least one symptomatic patient, and not found in general population data.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001193464 SCV001362315 pathogenic Hereditary breast ovarian cancer syndrome 2019-12-09 criteria provided, single submitter clinical testing Variant summary: PALB2 c.3048delT (p.Phe1016LeufsX17) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251448 control chromosomes (gnomAD). c.3048delT has been reported in the literature in individuals affected with breast and/or ovarian cancer (Zheng_2012, Tung_2014, Barrington_2018, Lu_2018). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five ClinVar submissions (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Division of Medical Genetics, University of Washington RCV000114587 SCV001424809 pathogenic Familial cancer of breast 2019-06-17 criteria provided, single submitter clinical testing This variant leads to a translational frameshift and the introduction of a premature termination codon 17 residues downstream. The variant transcript is predicted to be unstable and degraded by nonsense-mediated decay. Loss of expression of one allele of PALB2 is a well-established mechanism of disease for increased breast cancer risk (Rahman 2007, Janatova 2013, Antoniou 2014). This variant has an allele frequency of 0.000004 in the Broad Institute gnomAD Browser (https://gnomad.broadinstitute.org/). This variant has been reported in the literature in individuals with breast cancer (Zheng 2012, Churpek 2015, Tung 2015). Thus, this variant is interpreted as pathogenic.
Genetic Services Laboratory,University of Chicago RCV000412897 SCV002067396 likely pathogenic not provided 2019-11-15 criteria provided, single submitter clinical testing DNA sequence analysis demonstrated the presence of a heterozygous 1 base-pair deletion in the PALB2 gene, c.3048del. This sequence change results in an amino acid frameshift and creates a premature stop codon 16 amino acids downstream of the mutation, p.Phe1016Leufs*17. This deletion is predicted to result in an abnormal transcript, which may be degraded, or may lead to the production of a truncated PALB2 protein with potentially abnormal function. This sequence change has not been described in population databases (gnomAD, ExAC). The c.3048del sequence change has been identified in an African American woman with breast cancer, and a family history of colorectal cancer, leukemia, and pancreatic cancer (PMID: 21932393). This sequence change is likely causative of susceptibility to breast cancer and pancreatic cancer, however functional studies have not been performed to prove this conclusively.
Leiden Open Variation Database RCV000114587 SCV001193333 pathogenic Familial cancer of breast 2020-02-28 no assertion criteria provided curation Curators: Marc Tischkowitz, Arleen D. Auerbach. Submitters to LOVD: Marc Tischkowitz, Yukihide Momozawa.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.